Zobrazeno 1 - 8
of 8
pro vyhledávání: '"59"'
Autor:
Luciana Kikuchi, Alice M. Isejima, Paulo M. Hoff, Marcelo Queiroz, Leonardo Gomes da Fonseca, Maria Ignez Braghiroli, Joao Glasberg, Christian Kappeler, Luiz Antonio Senna Leite, Daniela R. Nebuloni, Giovanni M. Bariani, Rachel P. Riechelmann, Thomas Giollo Rivelli
Publikováno v:
The Oncologist. 24:1180-1187
Background Regorafenib is a multikinase inhibitor with antiangiogenic effects that improves overall survival (OS) in metastatic colorectal cancer (mCRC) after failure of standard therapies. We investigated the efficacy and safety of regorafenib in an
Autor:
Brandi G, de Rosa F, Agostini V, di Girolamo S, Andreone P, Bolondi L, Serra C, Sama C, Golfieri Rita, Gramenzi A, Cucchetti A, Ad, Pinna, Trevisani F, Biasco G, Italian Liver Cancer (ITA.LI.CA) Group
Publikováno v:
Europe PubMed Central
Background. Anti-angiogenic treatment with targeted agents is effective in advanced hepatocellular carcinoma (HCC). This trial evaluated the safety and efficacy of metronomic capecitabine in patients with HCC. Methods. This single-institution phase I
Publikováno v:
The Oncologist. 21:308-313
Introduction. Octreotide long-acting repeatable (LAR) is approved for the management of carcinoid syndromes and may improve progression-free survival of patients with well-differentiated neuroendocrine tumors (NETs). It is unknown whether the dosage
Autor:
Pritul Patel, Hem Desai, Diane Liu, Kimmie Tallie, Akhila Reddy, Eduardo Bruera, Jimin Wu, Janet L. Williams, Suresh K. Reddy, Seong Hoon Shin, Maxine de la Cruz, Vicki Gayle, Julio Silvestre, Joseph Arthur, Sriram Yennurajalingam, Marieberta Vidal, Jessica Waletich, Shalini Dalal, Kimberson Tanco, Eden Mae Rodriguez
Publikováno v:
BASE-Bielefeld Academic Search Engine
Purpose. Cancer pain management guidelines recommend initial treatment with intermediate-strength analgesics such as hydrocodone and subsequent escalation to stronger opioids such as morphine. There are no published studies on the process of opioid r
Autor:
Sam J. Lubner, Leonard Klein, Guang Yu Giang, J. Louis Hinshaw, Peter O'Dwyer, Ursina R. Teitelbaum, Mary F. Mulcahy, Jennifer Payne, Al B. Benson, Yang Feng, Philip J. Stella, Dustin A. Deming, Neal J. Meropol, Paul F. Engstrom
Publikováno v:
The Oncologist
Lessons Learned Rate of progression-free survival at a particular point in time, i.e., a landmark analysis, is a difficult endpoint for a heterogenous malignancy such as neuroendocrine cancer. Landmark analyses can also be complicated by evolution in
Autor:
Michael A. Carducci, Maya Ish-Shalom, Rony Weitzen, Roberto Pili, Daniel Keizman, Natalie Maimon, Maya Gottfried, Avivit Neumann, Hans J. Hammers, Avivit Peer, Ben Boursi, Wilmosh Mermershtain, Henry Hayat, Mario A. Eisenberger, Victoria J. Sinibaldi, Keren Rouvinov, Raanan Berger, Avishay Sella, Svetlana Kovel
Publikováno v:
The oncologist. 19(1)
Obesity, smoking, hypertension, and diabetes are risk factors for renal cell carcinoma development. Their presence has been associated with a worse outcome in various cancers. We sought to determine their association with outcome of sunitinib treatme
Autor:
José A. García-Sáenz, Lourdes Calvo, Lucía Heras, Anna González-Neira, Guillermo Pita, Ana Lluch, Manuel Constenla, Juan de la Haba, Montserrat Muñoz, Pilar Zamora, Miguel Martin, E.M. Guerra, Rosario Alonso, Rosalia Caballero, Eva Carrasco, Noelia Martínez, M. A. Jimeno, Julio César de la Torre-Montero, Jose Ignacio Chacon, Manuel Ruiz-Borrego, Manuel Ramos, Blanca Hernando, Daniela Caronia, Antonio Casado
Publikováno v:
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Background.The approved capecitabine regimen as monotherapyinmetastaticbreastcancer(MBC)is1,250mg/m 2 twice daily for 2 weeks on and 1 weekoff (Cint). Dose modifications are often required because of severe hand-foot syndrome (HFS).Wetestedacontinuou
Autor:
Chandra P. Belani, Veena Charu, Greg Rossi, Ali Ben-Jacob, Dianne Tomita, Mukesh Bhatt, Ahmad N. Gill
Publikováno v:
The oncologist. 12(6)
This randomized, controlled trial evaluated the effect of darbepoetin alfa on hospitalization days, transfusion requirements, hemoglobin levels, and fatigue in patients with anemia of cancer (AOC). Eligible patients were anemic (hemoglobin ≤11 g/dl